Opioid modulation of T-type Ca 2+ channel-dependent neuritogenesis/neurite outgrowth through the prostaglandin E 2 /EP 4 receptor/protein kinase A pathway in mouse dorsal root ganglion neurons

• Published in: Biochemical and biophysical research communications 2023-01, Vol.639, p.142
• Main Authors: Maeda, Takashi, Sekiguchi, Fumiko, Mitani, Kenji, Yamagata, Ryosuke, Tsubota, Maho, Yoshida, Shigeru, Kawabata, Atsufumi
• Format: Article
• Language: English
• Subjects: 1-Methyl-3-isobutylxanthine - pharmacology; Analgesics, Opioid - pharmacology; Animals; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases - metabolism; Dinoprostone - metabolism; Ganglia, Spinal - metabolism; Mice; Morphine - pharmacology; Neuralgia - metabolism; Neuronal Outgrowth; Neurons - metabolism; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin E, EP2 Subtype
• ISSN: 1090-2104

Irregular regeneration or inappropriate remodeling of the axons of the primary afferent neurons after peripheral nerve trauma could be associated with the development of neuropathic pain. We analyzed the molecular mechanisms for the neuritogenesis and neurite outgrowth caused by prostaglandin E (PGE ) in mouse dorsal root ganglion (DRG) neurons, and evaluated their opioid modulation. PGE in combination with IBMX, a phosphodiesterase inhibitor, caused neuritogenesis/neurite outgrowth in DRG cells, an effect abolished by a prostanoid EP , but not EP , receptor antagonist, and inhibitors of adenylyl cyclase or protein kinase A (PKA). Blockers of T-type Ca channels (T-channels), that are responsible for window currents involving the sustained low-level Ca entry at voltages near the resting membrane potentials and can be functionally upregulated by PKA, inhibited the neuritogenesis/neurite outgrowth caused by PGE /IBMX or dibutylyl cyclic AMP, a PKA activator, in DRG neurons, an inhibitory effect mimicked by ZnCl and ascorbic acid that block Ca 3.2, but not Ca 3.1 or Ca 3.3, T-channels. Morphine and DAMGO, μ-opioid receptor (MOR) agonists, suppressed the neuritogenesis and/or neurite outgrowth induced by PGE /IBMX in DRG neurons and also DRG neuron-like ND7/23 cells, an effect reversed by naloxone or β-funaltrexamine, a selective MOR antagonist. Our data suggest that the EP receptor/PKA/Ca 3.2 pathway is involved in the PGE -induced neuritogenesis/neurite outgrowth in DRG neurons, which can be suppressed by MOR stimulation. We propose that MOR agonists including morphine in the early phase after peripheral nerve trauma might delay the axonal regeneration of the primary afferent neurons but prevent the development of neuropathic pain.